Intensive end-of-life care in acute leukemia from a French national hospital database study (2017–2018)

Sébastien Salas1, Vanessa Pauly2, Margaux Damge1, Veronica Orleans2, Guillaume Fond2,3, Régis Costello4, Laurent Boyer2,3 and Karine Baumstarck3,5*

Abstract

Background: A better understanding of how the care of acute leukemia patients is managed in the last days of life would help clinicians and health policy makers improve the quality of end-of-life care. This study aimed: (i) to describe the intensity of end-of-life care among patients with acute leukemia who died in the hospital (2017–2018) and (ii) to identify the factors associated with the intensity of end-of-life care.

Methods: This was a retrospective cohort study of decedents based on data from the French national hospital database. The population included patients with acute leukemia who died during a hospital stay between 2017 and 2018, in a palliative care situation (code palliative care Z515 and-or being in a inpatient palliative care support bed during the 3 months preceding death). Intensity end-of-life care was assessed using two endpoints: High intensive end-of-life (HI-EOL: intensive care unit admission, emergency department admission, acute care hospitalization, intravenous chemotherapy) care and most invasive end-of-life (MI-EOL: orotracheal intubation, mechanical ventilation, artificial feeding, cardiopulmonary resuscitation, gastrostomy, or hemodialysis) care.

Results: A total of 3658 patients were included. In the last 30 days of life, 63 and 13% of the patients received HI-EOL care and MI-EOL care, respectively. Being younger, having comorbidities, being care managed in a specialized hospital, and a lower time in a palliative care structure were the main factors associated with HI-EOL.

Conclusions: A large majority of French young adults and adults with acute leukemia who died at the hospital experienced high intensity end-of-life care. Identification of factors associated with high-intensity end-of-life care, such as the access to palliative care and specialized cancer center care management, may help to improve end-of-life care quality.

Keywords: Acute leukemia, End-of-life care, Palliative care, Registry database, Health services research

Background

Despite the progress made in recent decades, cancer, including hematological malignancies, remains the leading cause of premature death in adults in France (Institut National du Cancer). Acute leukemia, a heterogeneous group of hematological malignancies characterized by the clonal and malignant proliferation of blasts, is responsible for bone marrow failure. Acute myeloid leukemia is generally diagnosed in patients over 60 years of age (median age 70 years), and its incidence increases with age [1]. Acute lymphoid leukemia is the most common cancer in children and accounts for only 20% of leukemia in adults [2]. Due to the nature of the disease
and the complications associated with intensive/aggressive treatments, such as allogeneic haematopoietic stem cell transplantation, patients with acute leukemia endure physical and psychological suffering throughout their treatment and their end-of-life care [3–6]. Although new therapies have emerged in recent years that have prolonged survival, many patients experience relapsed disease and die from their malignancy [1, 7, 8].

Since the 2000s, the quality of end-of-life care was improved with the integration of palliative care (https://www.who.int/cancer/palliative/definition/en/), characterized by a multidisciplinary approach in the management of patients with advanced or progressive chronic disease [6, 9]. However, at the end of life, compared with patients with solid tumors, previous studies showed that patients with hematological malignancies are less likely to access palliative care [4, 10–12], are less likely to enroll in a home care process or rehabilitation center [13, 14], and receive more intensive and aggressive care treatment ([13, 15–17], Johnston, [18] #32, [19, 20]). Several possible explanations for this finding have been suggested: disease-related complications similar to treatment-related complications, sudden and uncertain transitions to a palliative approach to care, strong bonds between staff and patients, hematologic oncologists who are less comfortable discussing death and dying, and unrealistic clinician and/or patient expectations [11, 15, 17].

Among the previous studies, some report data older than 10 years [4, 11–13, 16], from a single center [4, 12, 16], from heterogeneous individuals [19], or focused on old [21] or young populations [18, 20]. Few of them specifically explored patient- and hospital-related factors associated with intensive care treatments at the end of life. In France, a better understanding of how the care of acute leukemia is managed in the last days of life would help clinicians and health policy makers improve the quality care during this special period, while taking into account the wishes of the patients and their families.

This study provides robust and recent information from the French national hospital database about the intensity of care near the end of life for patients with acute leukemia. The objectives of this study were: (i) to describe the intensity of end-of-life care among adult patients (and adolescents) with acute leukemia who died in the hospital from 2017 to 2018; and (ii) to identify the factors associated with the intensity of end-of-life care.

Methods
Data source
This was a French population-level retrospective cohort study based on data extracted from the French national hospital database (Programme de Médicalisation des Systèmes d’Information, PMSI). The PMSI is an exhaustive public and private hospital database inspired from the US Medicare system. The PMSI is based on diagnosis-related groups with compulsory information for each hospital stay including socio-demographic characteristics of patient, diagnoses using the International Classification of Diseases, tenth revision (ICD-10), and procedures using the French classification of medical acts (Classification Commune des Actes Médicaux, https://www.ameli.fr/accueil-de-la-ccam/index.php). -The reliability and validity of PMSI data have already been assessed. This data source was previously used in similar studies [20, 22–24].

Population
The study population included all patients with acute leukemia aged 18 years and older who died during a hospital stay between January 1, 2017, and December 31, 2018. The patients were identified using the algorithm developed by the French National Cancer Institute (INCa, https://aide.groupepsihs.com/docs/pmsi-pilot-cancero/principes-generaux/algorithm-inca/, last access 2021, October, 31th), which was specifically designed to identify cancer patients with routinely collected data (codes of diagnosis, codes of medical acts) (Additional file 1). The selection of patients was based on the ICD-10 leukemia-related codes (Additional file 1). The population included only patients in a palliative care situation defined by at least: 1. one code Z515 during the 3 months preceding death (Z515 can be used by the coders if the patient has a palliative care consultant during the hospitalization but also if the healthcare team considers the patient in a palliative phase); and-or 2. being in an inpatient palliative care support bed during the 3 months preceding death (in France, a palliative bed is a bed in a palliative care unit or a bed in another care unit dedicated to a palliative patient). In France, the palliative teams are only assisting with symptom management (not addressing the intensity of care). The patients with a combination of myeloid and lymphoid leukemia were excluded due to: 1) worse prognosis, 2) heterogeneous therapeutic strategies.

Endpoints
Intensity end-of-life care was assessed using two endpoints: high intensive end-of-life (HI-EOL) care and Most Invasive End-of-Life (MI-EOL) care. HI-EOL care and MI-EOL care definitions were proposed by Earle et al. [13, 25, 26] and jointly endorsed by the National Quality Forum and the American Society of Clinical Oncology.

HI-EOL care is defined by the occurrence of at least one of the following indicators: 1. at least one intensive care unit (ICU) admission in the last 30 days of life; 2. more than one emergency department admission in the
last 30 days of life; 3. more than one acute care hospitalization in the last 30 days of life; or 4. at least one intravenous chemotherapy treatment in the last 14 days of life.

MI-EOL care is defined by the occurrence of at least one of the following indicators in the last 30 days of life: 1. orotracheal intubation; 2. mechanical ventilation; 3. artificial feeding (enteral or parenteral); 4. cardiopulmonary resuscitation; 5. gastrostomy; or 6. Hemodialysis.

Factors associated with end-of-life care intensity
The factors are detailed in the Additional file 1.

Statistical analysis
The rates of patients receiving HI-EOL care, MI-EOL care, and each constitutive element are provided. To assess the associations between the two endpoints (HI-EOL and MI-EOL, used as separate dependent variables) and sociodemographic, clinical, and hospital data, univariate and multivariate analyses were performed. Variables selected for the multivariate models were: age classes, sex, year of death, social living area, type of leukemia, allogeneic stem cell transplantation, comorbidities, type of hospital, time in a palliative care structure, time between the patients’ home and the hospital, and length of stay. A generalized estimating equation (GEE) was performed to estimate the parameters while taking into account the intrahospital cluster effect (PROC GLIMMIX procedure model, SAS V9.4). The results are presented as adjusted odds ratios (AORs) and their 95% confidence intervals (95% CIs). Statistical significance was defined as $p < 0.05$. Statistical analysis was performed with SAS 9.4 (SAS Institute).

Results

Sample
A total of 3658 patients who died at the hospital between January 1, 2017 and December 31, 2018 were included in the study. We excluded 376 patients with unspecified acute leukemia, 116 patients with a combination of myeloid and lymphoid leukemia, and 3252 patients not in a palliative care situation. A flow diagram detailing the selection of cases is shown in Fig. 1. Twenty-nine percent of the patients were aged under 70 years at the time of death and they were predominantly men (56%). A majority (55%) of the population was living in a socially disadvantaged area. The patients predominantly presented with acute myeloid leukemia (94%) and 7% of them had undergone allogeneic stem cell transplantation. Almost 15% of the patients died in an intensive care structure, 25% of them were hospitalized for more than 1 month, and 30% spent time more than 1 month in a palliative care structure before death. All details are shown in Table 1.

Intensity of end-of-life care
In the last 30 days of life, 63 and 13% of the patients received HI-EOL care and MI-EOL care, respectively. For 20% of the patients, care was managed in an intensive care unit, and 11% of them were mechanically ventilated. All the items constituting HI-EOL/MI-EOL care are presented in Fig. 2.

Factors associated with HI-EOL care and MI-EOL care
Age, sex, year of death, social living area, type of leukemia, allogeneic stem cell transplantation, comorbidities, type of hospital, time in a palliative care structure, time between the patients’ home and hospital, and length of stay were entered in the multivariate models to assess factors associated with HI-EOL and MI-EOL. HI-EOL care was more often received by younger individuals. The patients with a higher number of comorbidities, hospitalization in specialized cancer centers, a lower time in a palliative care structure, and a longer length of stay were more often associated with HI-EOL care. MI-EOL care was also more often used for younger patients, men, and patients living in a disadvantaged area. The patients with acute myeloid leukemia, a lower time in a palliative care structure, and a longer length of stay were more often associated with MI-EOL care. The multivariate analysis results are detailed in Table 2.

Discussion
The first important finding of this study was the high proportion of high intensive end-of-life care (63%) during the last days before death in French patients presenting with acute leukemia who died in the hospital. The proportion of most intensive end-of-life care according to the Earle definition was, in contrast, lower (13%). These findings were close to those of studies conducted in similar populations. In the study conducted by Beaussant et al. [19], based on the same French national hospital register but focusing on an older period (2010–2013) and on a larger panel of hematological malignancies (including acute leukemia), some results are relatively consistent with our findings: 26% of patients received a chemotherapy in the last month versus 20% in our results, artificial feeding was used for 7% versus 3% in our cohort, dialysis was used in 5% versus 1% in our study, cardiopulmonary resuscitation was used for less than 2% versus 1.7% in our study. Likewise, in recent studies [18, 20] exploring younger populations (children, adolescents, and young adults with cancer), the authors observed high rates of patients who experienced intensive end-of-life care with significantly higher risk for the group with hematological...
malignancies. Higher rates were reported in other studies, but they included smaller samples, older patients, and data older than 10 years [16, 21].

These high rates of aggressive end-of-life care may be partially explained. First, in comparison with patients who presented with other malignancies, patients with hematological malignancies (especially patients with acute leukemia) present with a high frequency of hematological complications (bleeding, thromboembolic events, and severe anemia). These complications require emergency treatments, such as transfusions, intravenous antibiotic infusions, and other acute interventions, such that the hospital is often the more comfortable place for treatment administration and monitoring. Second, hematologic oncologists present specificities in their attitudes and beliefs toward end-of-life care. Compared with solid tumor specialists, they are more likely to recommend cancer therapy to patients with poor performance status and short expected survival, and they are less comfortable with end-of-life care [15]. Even if hematologic...
oncologists report the ability to identify key points in the disease trajectory signifying that end of life is near, they report the absence of a clear definition of the end of life for hematological cancers [15]. Hematologic oncologists report feeling a sense of failure when they are not able to alter the course of disease [15] and have more difficulties sharing prognosis and transition in care with their patients than other oncologists [17]. End-of-life discussions in hematologic oncology often occur too late [17]. It has been shown that focused communication skills training can improve physicians’ abilities to empathically help patients achieve their goals while balancing benefits and burdens [27]. Third, two kinds of aggressive care [17] should be distinguished. Some aspects of intensive care may be considered physician-initiated events (such as hospital admission, chemotherapy administration, intubation) that are influenced by advance care discussions between physicians and patients. Conversely, the decision to present to an emergency unit largely depends on patients and their families themselves and is less likely amenable to physician-driven process intervention. This distinction deserves to be emphasized in future perspectives on improving end-of-life care quality. While some barriers can be reduced with physicians’ interventions, others need discussions with the patients. This highlights the importance of engagement in advance care planning processes [28, 29] that are still insufficient for cancer patients [30].

Table 1 Socio-demographic, clinical, and hospital characteristics of the 3658 patients

| Socio-demographic data | N (%) |
|------------------------|-------|
| Age at death (years)   |       |
| < 60                   | 417 (11.4) |
| [60–70]                | 623 (17.0) |
| (70–80]                | 1150 (31.4) |
| ≥ 80                   | 1468 (40.1) |
| Sex                    |       |
| Male                   | 2037 (55.7) |
| Female                 | 1621 (44.3) |
| Year of death          |       |
| 2017                   | 1813 (49.6) |
| 2018                   | 1845 (50.4) |
| Social area living     |       |
| Socially advantaged    | 1608 (44.0) |
| Socially disadvantaged  | 2001 (54.7) |
| Missing data           | 49 (1.3)  |

| Clinical Data | N (%) |
|---------------|-------|
| Type of leukemia |       |
| Acute myeloid leukemia | 3426 (93.7) |
| Acute promyelocytic leukemia | 20 (0.6)  |
| Acute myelomonocytic leukemia | 170 (4.7) |
| AML with 11q23 | 19 (0.5) |
| AML with dysplasia of several cell lines | 161 (4.4) |
| Acute monoblastic/monocytic leukemia | 123 (3.4) |
| Acute pan myelosis with myelofibrosis | 72 (2.0)  |
| Megakaryocyte leukemia | 22 (0.6) |
| Acute erythroid leukemia | 31 (0.9)  |
| Acute lymphoid leukemia | 231 (6.3) |
| Months between diagnosis and death |       |
| ≤ 3 | 703 (19.2) |
| [3–12] | 806 (22.0) |
| [12–36] | 1084 (29.6) |
| > 36 | 1065 (29.1) |
| Allogeneic stem cell transplantation |       |
| No | 3394 (92.8) |
| Yes | 264 (7.2)  |
| Charlson score (co-morbidities) a |       |
| 0 | 1459 (39.9) |
| 1–2 | 1411 (38.6) |
| ≥ 3 | 788 (21.5)  |
| Last hospitalization stay | N (%) |
| Type of hospital c |       |
| Non-specialized hospital | 2245 (61.4) |
| Specialized hospital | 1413 (38.6) |
| Death in an intensive care structure | 495 (13.5) |
| Palliative care structure in the last 3 days of life b | 745 (20.4) |
| Time in a palliative care structure before death |       |
| ≤ 1 month | 2545 (69.6) |
| > 1 month | 1113 (30.4) |

Table 1 (continued)

Travel time from patients’ home (minutes)

| Travel time from patients’ home (minutes) | N (%) |
|------------------------------------------|-------|
| ≤ 10 | 1047 (28.6) |
| [10–30] | 1071 (29.3) |
| [30–60] | 652 (17.8) |
| > 60 | 945 (25.1) |
| Length of stay (days) |       |
| ≤ 15 | 1382 (37.8) |
| [15–30] | 1361 (37.2) |
| > 30 | 929 (25.0) |

a Charlson modified score (excluding malignancies/metastasis)
b Intensive care structure includes intensive care unit, resuscitation unit, emergency unit
c Specialized centers include cancer units of an university hospital and units of a cancer hospital, non-specialized centers include all the other cases
A third finding drew our attention. A earlier introduction of a palliative care management was a real benefit to protect against aggressive end of life care, as already described in previous studies [32, 33] including randomized trials [9, 34]. Even if having care managed by a palliative structure did not totally protect against invasive/aggressive care during the last days of life [35], earlier palliative intervention had a positive impact on treatment aggressiveness [34]. Nevertheless, as this approach was less often discussed, it is urgent to convince a greater number of centers to plan an earlier transition from curative interventions to palliative care. Qualitative studies may help to identify barriers [36] and provide targeted actions.

Other less expected associations with intensive end-of-life care were found. We hypothesized that the presence of comorbidities, as a reflection of worse health status, would be associated with less intensive end-of-life care, but we found the opposite result. Likewise, compared with nonspecialized cancer centers, we hypothesized that specialized cancer centers, by incorporating multidisciplinary teams, would be less associated with high intensity care [20]. These counterintuitive results may reflect the difficulty of transitioning from curative to palliative objectives. It is now necessary to combine the most advanced technology and therapeutics (such as targeted therapies or allogeneic stem cell transplantation) with consideration of the best end-of-life care quality. Interestingly, the oldest patients were those who benefited least from intensive end-of-life care: this finding was also found in previous reports [20].

**Strengths and limitations**

The main strengths are as follows: (1) The study is the first study focusing on acute leukemia in a palliative care situation; and (2) The study includes a large population enrolled in recent years (2017–2018). Some limitations should be discussed: (1) Only patients who died in hospitals were studied, and future studies should explore the phenomenon in other conditions of death, such as patients whose care was managed in rehabilitation centers and at home. This would provide a more valid picture of patients with acute leukemia at the end of life, providing factors associated with the risk of dying in hospitals in France. This may also help improve coordination within the health care delivery system, including specific and general hospitals and ambulatory care. (2) The retrospective design prevented us from truly exploring the relations between the expected prognosis of the patient and the decision.
## Table 2  Factors associated with High Intensive End-of-Life (HI-EOL) and Most Invasive End-of-Life (MI-EOL) care (Multivariate Analyses)

|                | HI-EOL | MI-EOL |
|----------------|--------|--------|
|                | N = 2316 (63.31%) | N = 471 (12.88%) |
|                | N (%) | AOR (CI 95%) | p-value | N (%) | AOR (CI 95%) | p-value |
| Age at death (years) |        |          |         |        |          |         |
| < 60 (ref)     | 315 (75.5) | –        |         | 94 (22.5) | –        |         |
| [60-70)       | 459 (73.7) | 0.968 (0.708–1.325) | 0.841 | 124 (19.9) | 0.959 (0.686–1.341) | 0.807 |
| [70-80]       | 734 (63.8) | 0.688 (0.512–0.926) | 0.014 | 128 (11.3) | 0.558 (0.394–0.791) | 0.001 |
| ≥ 80          | 808 (55.0) | 0.536 (0.400–0.720) | < 10⁻³ | 125 (8.51) | 0.445 (0.311–0.635) | < 10⁻³ |
| Sex            |        |          |         |        |          |         |
| Man (ref)     | 1324 (65.0) | –        |         | 278 (13.7) | –        |         |
| Woman         | 992 (62.1) | 0.891 (0.770–1.033) | 0.125 | 193 (11.9) | 0.940 (0.761–1.161) | 0.567 |
| Year of Death |        |          |         |        |          |         |
| 2017 (ref)    | 1126 (62.1) | –        |         | 220 (12.1) | –        |         |
| 2018          | 1190 (64.5) | 1.072 (0.928–1.239) | 0.346 | 251 (13.6) | 1.104 (0.899–1.356) | 0.344 |
| Social area living |        |          |         |        |          |         |
| Socially advantaged (ref) |  |  | | | | |
| Socially disadvantaged |  |  | | | | |
| Type of leukemia |        |          |         |        |          |         |
| Acute myeloid leukemia (ref) |  |  | | | | |
| Acute lymphoid leukemia |  |  | | | | |
| Allo-SCT       |        |          |         |        |          |         |
| No (ref)       | 2109 (62.1) | –        |         | 400 (11.8) | –        |         |
| Yes            | 207 (78.4) | 1.186 (0.832–1.692) | 0.345 | 71 (26.9) | 1.335 (0.934–1.906) | 0.113 |
| Charlson score (co-morbidities) a |        |          |         |        |          |         |
| 0 (ref)        | 870 (59.66) | –        |         | 149 (10.2) | –        |         |
| 1–2            | 939 (66.6) | 1.300 (1.104–1.532) | < 10⁻³ | 190 (13.5) | 1.317 (1.033–1.679) | 0.003 |
| ≥ 3            | 507 (64.3) | 1.142 (0.939–1.89) | 0.184 | 132 (16.8) | 1.720 (1.312–2.53) | < 10⁻³ |
| Type of hospital b |        |          |         |        |          |         |
| Non-specialized hospital (ref) |  |  | | | | |
| Specialized hospital |  |  | | | | |
| Time in a palliative care structure |        |          |         |        |          |         |
| ≤ 1 month (ref) | 161 (63.3) | –        |         | 336 (13.2) | –        |         |
| > 1 month      | 705 (63.3) | 0.577 (0.481–0.690) | < 10⁻³ | 135 (12.1) | 0.659 (0.509–0.853) | 0.002 |
| Time from patients' home (minutes) |        |          |         |        |          |         |
| ≤ 10 (ref)    | 617 (58.9) | –        |         | 108 (10.3) | –        |         |
| [10–30)       | 684 (63.9) | 1.224 (1.017–1.474) | 0.032 | 131 (12.2) | 1.164 (0.79–1.542) | 0.289 |
| [30–60)       | 404 (62.0) | 1.114 (0.897–1.382) | 0.330 | 81 (12.4) | 1.161 (0.840–1.764) | 0.366 |
| > 60          | 537 (67.5) | 1.205 (0.977–1.486) | 0.081 | 138 (17.3) | 1.335 (0.934–1.906) | 0.113 |
| Length of stay (days) |        |          |         |        |          |         |
| < 7 (ref)     | 250 (47.1) | –        |         | 46 (10.4) | –        |         |
| [7–15)        | 514 (60.3) | 2.114 (1.650–2.709) | < 10⁻³ | 81 (10.0) | 0.910 (0.608–1.361) | 0.645 |
| [15–30)       | 936 (68.8) | 4.053 (3.212–5.114) | < 10⁻³ | 197 (13.2) | 1.159 (0.807–1.663) | 0.425 |
| > 30          | 704 (76.9) | 7.104 (5.389–9.365) | < 10⁻³ | 147 (16.1) | 1.474 (0.994–2.186) | 0.054 |

HI-EOL: High Intensive End-of-Life (at least one of the following indicators: 1. at least one intensive care unit (ICU) admission in the last 30 days of life; 2. more than one emergency department admission in the last 30 days of life; 3. more than one acute care hospitalization in the last 30 days of life; or 4. at least one intravenous chemotherapy treatment in the last 14 days of life)

MI-EOL: Most Invasive End-of-Life (at least one of the following indicators in the last 30 days of life: 1. orotracheal intubation; 2. mechanical ventilation; 3. artificial feeding (enteral or parenteral); 4. cardiopulmonary resuscitation; 5. gastrostomy; or 6. hemodialysis)

Allo-SCT: Allogeneic stem cell transplantation

AOR (95% CI): adjusted odd ratio (95% confidence interval)

a Charlson modified score (excluding malignancies/metastasis)

b Specialized centers include cancer units of an university hospital and units of a cancer hospital, non-specialized centers include all the other cases

ref: reference modality for the AOR

Bold values: p-value < 0.05
regarding intensive care treatments, such as chemotherapy administration, intensive care unit admission, and mechanical ventilation implementation. Physicians have been found to be overoptimistic regarding the prognosis of terminally ill patients [37]. (3) The accuracy of the findings, due to the source of the data (an administrative registry), depends on the coding rules and the skills of the coders [38]. These databases were originally designed for the optimization of funding allocation for the French health facilities, but the coding procedures have moved progressively towards those of a medical record database.

Conclusion
A majority of French adults, young adults, and adolescents with acute leukemia in a palliative care situation who died at the hospital, experienced high-intensity end-of-life care. Identification of factors associated with intensity end-of-life care, such as the access to palliative care and specialized cancer center care management, may help to improve end-of-life care quality.

Abbreviations
AORs: Adjusted odds ratios; EOL: End-of-life; HI-EOL care: High intensive end-of-life care; ICD-10: Classification of Diseases, tenth revision; INCa: French National Cancer Institute; MI-EOL care: Most invasive end-of-life care; PMSI: Programme de Médicalisation des Systèmes d’Information.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12904-022-00937-0.

Declarations

Ethics approval and consent to participate
All methods were carried out in accordance with relevant French and European guidelines and regulations. Since 16 July 2018, the French National Data Protection Committee (CNIL) published revised and new reference methods regarding data processing in health research to adapt the existing framework to the EU General Data Protection Regulation (GDPR) and the national health data system (SNDS). MR-005 declaration is necessary to access to the programme for the medicalisation of information systems (PMSI) as in our study. This study was approved by the French National Data Protection Committee (CNIL); authorization number MR00S N°15160102192019. Informed consent was not obtained because the PMSI database is anonymous.

Consent for publication
Not applicable.

Competing interests
The authors have declared no conflicts of interest.

Author details
1 Department of Palliative Care, Oncology, APHM, Marseille, France. 2 Department of Medical Information, APHM, Marseille, France. 3 CEReSS - Health Service Research and Quality of Life Center, Aix-Marseille University, EA 3279, 27 bd Jean Moulin, cedex 05, F-13385 Marseille, France. 4 Hematology and Cellular Therapy Department, APHM, Marseille, France. 5 Department of Epidemiology and Health Economics, APHM, Marseille, France.

Received: 25 May 2021 Accepted: 25 March 2022

References
1. Short NJ, Ryting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
2. Torpy JM, Lynnm C, Glass RM. JAMA patient page. Acute lymphoblastic leukemia. JAMA. 2009;301(4):452.
3. Epstein AS, Goldberg GR, Meier DE. Palliative care and hematologic oncology: the promise of collaboration. Blood Rev. 2012;26(6):233–9.
4. Fadul NA, El Osta B, Dalal S, Poulter VA, Buera E. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med. 2008;11(3):422–7.
5. Manitta VJ, Philip JA, Cole-Sinclair MF. Palliative care and the hematologic oncology patient: can we live together? A review of the literature. J Palliat Med. 2010;13(8):1021–5.
6. Zimmermann C, Yuen D, Mischtelte A, Minden MD, Brandwein JM, Schimmer A, et al. Symptom burden and supportive care in patients with acute leukemia. Leuk Res. 2013;37(7):731–6.
7. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908–15.
8. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
9. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.
10. Maddocks I, Bentley L, Sheedy J. Quality of life issues in patients dying from haematological diseases. Ann Acad Med Singap. 1994;23(2):244–8.
11. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25(6):630–41.
12. Alt-Epping B, Wulf G, Nauck F. Palliative care for patients with hematological malignancies—a case series. Ann Hematol. 2011;90(5):613–5.
13. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26(23):3960–6.
14. Howell DA, Roman E, Cox H, Smith AG, Patmore R, Garry AC, et al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care. 2010;9.

15. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015;26(7):1440–6.

16. Hui D, Didwaniya N, Vidal M, Shin SH, Chisholm G, Roquemore J, et al. Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014;120(10):1572–8.

17. Odejide OG, Cronin AM, Condon NB, Fletcher SA, Earle CC, Tulsky JA, et al. Barriers to quality end-of-life care for patients with blood cancers. J Clin Oncol. 2016;34(26):3126–32.

18. Johnston EE, Alvarez E, Saynina O, Sanders L, Bhatia S, Chamberlain LJ. End-of-life intensity for adolescents and young adults with cancer: a Californian population-based study that shows disparities. J Oncol Pract. 2017;13(9):e770–81.

19. Beausant Y, Daguie F, Chauchet A, Rochigneux P, Tournigand C, Aubry R, et al. Hospital end-of-life care in hematological malignancies. BMJ Support Palliat Care. 2018;8(3):314–24.

20. Revon-Riviere G, Pauly V, Baumstarck K, Bernard C, Andre N, Gentet JC, et al. High-intensity end-of-life care among children, adolescents, and young adults with cancer who die in the hospital: a population-based study from the French national hospital database. Cancer. 2019;125(13):2300–8.

21. El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015;121(16):2840–8.

22. Boudemaghe T, Belhadj I. Data resource profile: the French National Uniform Hospital Discharge Data set Database (PMSI). Int J Epidemiol. 2017;46(2):392–392d.

23. Fond G, Pauly V, Duba A, Salas S, Viprey M, Baumstarck K, et al. End-of-life breast cancer care in women with severe mental illnesses. Sci Rep. 2021;11(1):10167.

24. Viprey M, Pauly V, Salas S, Baumstarck K, Orleans V, Llorca PM, et al. Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. Eur Psychiatry Clin Neurosci. 2021;27(8):1571–8.

25. Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133–8.

26. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–21.

27. Dharmarajan KV, Wei R, Vapiwala N. Primary palliative care education in specialty oncology training: more work is needed. JAMA Oncol. 2016;2(7):858–9.

28. Kelly EP, Henderson B, Hyer M, Pawlik TM. Intrapersonal factors impact advance care planning among Cancer patients. Am J Hosp Palliat Care. 2011;28(8):907–913.

29. Marchi L, Santos Neto MDO, Moraes JP, Paiva CE, Paiva CSR. Influence of advance directives on reducing aggressive measures during end-of-life cancer care: a systematic review. Palliat Support Care. 2021;19(3):348–354.

30. Boulanger A, Chabal T, Fichaux M, Destandau M, La Piana JM, Auquier P, et al. Opinions about the new law on end-of-life issues in a sample of French patients receiving palliative care. BMC Palliat Care. 2017;16(1):7.

31. Johnston EE, Muffy L, Alvarez E, Saynina O, Sanders LM, Bhatia S, et al. End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: a population-level analysis. J Clin Oncol. 2018;36(30):3023–30.

32. Pritchard S, Cuvelier G, Harlos M, Barr R. Palliative care in adolescents and young adults with cancer. Cancer. 2011;117(10 Suppl):2323–8.

33. Colombert I, Bouleuc C, Piolot A, Vilflautot A, Jaulmes H, Voisin-Salteil S, et al. Group Es: multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. BMC Palliat Care. 2019;18(1):35.

34. Maltoni M, Scarpi E, Dall’Agata M, Schiavon S, Biasini C, Codeca C, et al. Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016;69:110–8.

35. Cheng BH, Sham MM, Chan KY, Li CW, Au HY. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32(2):221–5.

36. LeBlanc TW, Egan PC, Oliszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132(7):717–26.

37. Glare P, Vink K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195–8.

38. Anthun KS, Bjornagard JH, Magnusen J. Economic incentives and diagnostic coding in a public health care system. Int J Health Econ Manag. 2017;17(1):83–101.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.